AstraZeneca Pharma India Surges Over 4% on Approval for Trastuzumab deruxtecan Import

27 Mar 2024 , 12:53 PM

AstraZeneca Pharma India witnessed a surge of over 4% on March 27 following the announcement of receiving approval from the Central Drugs Standard Control Organisation.

The approval allows the company to import, sell, and distribute Trastuzumab deruxtecan lyophilized powder concentrate for solution for infusion 100mg (Enhertu).

At the time of reporting, AstraZeneca Pharma shares were trading at ₹5273.55, reflecting a 3.61% increase compared to the previous close.

“The receipt of this permission paves the way for the launch of Trastuzumab deruxtecan lyophilized powder for concentrate for solution for infusion 100mg (Enhertu) in India for the specified additional indications, subject to the receipt of related statutory approvals, if any,” said AstraZeneca Pharma.

Trastuzumab deruxtecan is prescribed for adult patients with unresectable or metastatic HER2-Low (IHC 1+ or IHC 2+/ISH-) breast cancer who have undergone prior chemotherapy in the metastatic setting or developed disease recurrence within 6 months of completing adjuvant chemotherapy.

Additionally, it is indicated for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have previously received a trastuzumab-based regimen.

AstraZeneca Pharma stated that the approval sets the stage for the launch of Trastuzumab deruxtecan in India for the specified additional indications, contingent upon receiving any related statutory approvals.

For feedback and suggestions, write to us at [e-mail]